Israeli firm forming umbrella ultrasound companyElscint parent Elbit has big plans for ultrasound, and it doesnot intend to stop with its purchase of Diasonics. Elbit revealedlast week that it has added to its Diasonics acquisition withthe
Elscint parent Elbit has big plans for ultrasound, and it doesnot intend to stop with its purchase of Diasonics. Elbit revealedlast week that it has added to its Diasonics acquisition withthe purchase of Australian vendor Ausonics.
Elbit intends to merge Diasonics, Ausonics and Elscint's Elscintecultrasound subsidiary under a single umbrella unit with a fullrange of products, according to Jackob (Kobi) Vortman, sales managerof Elscintec. Elbit has not yet decided on a name for the unitit is building, but retaining the Diasonics label is one possibility,Vortman said.
"Ausonics was purchased as part of a strategy to buildan ultrasound company that will eventually cover a wide spectrumof products and capabilities," Vortman told SCAN. "Theintention is to cross-fertilize all these organizations usingtechnology know-how developed in each of them."
Elbit last month announced its plan to buy Diasonics in aneffort to build its medical imaging subsidiary's presence in ultrasound,which until now had been minimal (SCAN 7/27/94). Elbit boughtAusonics from the vendor's parent firm, Pacific Dunlop, a $4.5billion Australian conglomerate. The purchase was completed inMay, but Elbit delayed an announcement of the acquisition untilthe Diasonics deal was finalized, Vortman said.
Ausonics markets Opus 1, a low-end portable ultrasound scanner.It is awaiting Food and Drug Administration 510(k) clearance forOpus 2, also a portable black-and-white scanner. Ausonics introducedthe unit at last year's Radiological Society of North Americameeting. The scanner is intended for general radiology, ob/gynand urology applications.
Ausonics scanners are currently offered through a dealer network.Elbit will probably expand that network rather than build a directsales effort for the products. Ausonics sells about 200 systemsa year and has an installed base of several thousand.
Acquiring Ausonics gives Elbit a lower mid-range scanner tocomplement the premium VST Masters Series offering from Diasonicsand Elscintec's mid-range ESI 5000 scanner. The ESI 5000 is beingmodified with technology acquired from the Diasonics purchase,Vortman said.
Elbit is making a determined push in ultrasound because thecompany wants to focus on medical imaging, and ultrasound is thelargest imaging modality. Ultrasound's share of the imaging pieis likely to grow even larger in the future, according to Vortman.
"From a strategic point of view, we believe that the medicalimaging market will remain a major market with a definite focuson high technology," Vortman said. "There was a strategicdecision to go in and try to build a real (ultrasound) capability."
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.